A combination endovascular device:thrombectomy with localized hypothermia

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$207,200.00
Award Year:
2011
Program:
SBIR
Phase:
Phase I
Contract:
1R43NS073291-01
Award Id:
n/a
Agency Tracking Number:
R43NS073291
Solicitation Year:
2011
Solicitation Topic Code:
NINDS
Solicitation Number:
PA10-050
Small Business Information
25 LYNNFIELD DR, EAST WINDSOR, NJ, 08520-2407
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
607333536
Principal Investigator:
THOMAS MERRILL
(856) 256-4301
tlmerrill@comcast.net
Business Contact:
THOMAS MERRILL
(609) 558-1169
tlmerrill@comcast.net
Research Institute:
Stub




Abstract
DESCRIPTION (provided by applicant): Stroke is the 3rd leading cause of death and number one cause of adult disability in the United States. The primary goal of ischemic stroke treatment is quickly restoring blood perfusion. However, studies have shown that this return of blood flow, while necessary to bettering patient outcome, can cause damage to local tissue. Hypothermia has been shown to decrease this reperfusion injury . The overall goal of this proposed research is to use therapeutic hypothermia to augment the tissue salvage capabilities of existing mechanical clot removal devices that restore perfusion by reducing reperfusion injury. Our proposed device is a cooling guide catheter which will function identically to conventional guide catheters but with blood cooling capabilities to save ischemic tissue at risk of reperfusion injury. Specific Aims: 1.) Design a cooling guide catheter that can be used with existing mechanical clot removal devices and that can quickly reduce target tissue temperatures, 2.) characterize device thermal-fluid performance in an in vitro brain model, and 3.) demonstrate that the cooling catheter can safely and effectively decrease target tissue temperature in a small animal pilot study. To achieve these aims the following willbe performed: thermal-fluid modeling, design input requirements and feasibility points, development of prototype designs, coolant pressure-flow behavior characterization, in vitro thermal-fluid performance testing for each prototype in system that mimicsintracranial blood flow, and in vivo testing demonstrating that rapid localized tissue cooling is feasible and that the catheter is hemocompatibile with no significant damage to vessels or tissue. Relevance: The technological innovation of combining stroketreatment therapies - mechanical clot removal and reperfusion hypothermia - may yield synergistic benefits, resulting in reduced infarct size and improved neurological outcomes compared to outcomes using either technology separately. If fast and safe cooling is shown feasible in Phase I, Phase II would investigate efficacy using an animal stroke model. PUBLIC HEALTH RELEVANCE: Stroke is the 3rd leading cause of death and number one cause of adult disability in the United States. For stroke treatment, quickly restoring blood flow has been shown to improve outcome, although some experts have found reperfusion injury mitigates these benefits. FocalCool, LLC seeks to combine two technologies, thrombectomy and therapeutic hypothermia using a novel coolingguide catheter potentially maximizing the benefit of blood flow restoration while minimizing damaging effects of reperfusion injury.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government